Lantheus Holdings Inc (NASDAQ:LNTH) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $24.50.
LNTH has been the topic of several research analyst reports. ValuEngine lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research raised Lantheus from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, January 3rd. BidaskClub lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Wells Fargo & Co raised Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday, November 2nd. Finally, Credit Suisse Group lifted their price target on Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd.
Shares of Lantheus (NASDAQ:LNTH) opened at $23.48 on Friday. The company has a debt-to-equity ratio of -3.41, a quick ratio of 2.46 and a current ratio of 2.96. Lantheus has a 12-month low of $7.95 and a 12-month high of $24.10. The firm has a market capitalization of $880.45 and a PE ratio of 29.35.
Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.04. The business had revenue of $79.94 million for the quarter, compared to analyst estimates of $77.18 million. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $0.15 EPS. research analysts forecast that Lantheus will post 1.05 earnings per share for the current fiscal year.
In other news, SVP Timothy G. Healey sold 11,314 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total value of $243,364.14. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael P. Duffy sold 21,655 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $22.40, for a total value of $485,072.00. Following the completion of the transaction, the insider now directly owns 156,784 shares in the company, valued at approximately $3,511,961.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,886 shares of company stock worth $986,201. 2.30% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in shares of Lantheus in the second quarter valued at approximately $117,000. Sei Investments Co. increased its holdings in shares of Lantheus by 189.6% in the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 5,126 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Lantheus in the second quarter valued at approximately $141,000. BNP Paribas Arbitrage SA acquired a new position in shares of Lantheus in the second quarter valued at approximately $146,000. Finally, LS Investment Advisors LLC increased its holdings in shares of Lantheus by 47.1% in the third quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,981 shares during the period. 91.91% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Lantheus Holdings Inc (LNTH) Receives Average Recommendation of “Buy” from Analysts” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/05/lantheus-holdings-inc-lnth-receives-average-recommendation-of-buy-from-analysts.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.